Skip to contentF
Fulcrum Therapeutics, Inc.
F
FULCFulcrum Therapeutics, Inc. Q2 2024 · 10-Q
Revenue$80.00M$80.00Mno prior Q2 2023 on file Net Income$55.41M$55.41Mno prior Q2 2023 on file EPS Diluted$0.87$0.87no prior Q2 2023 on file Operating Income$52,492,000— Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Fulcrum Therapeutics, Inc. · CIK 1680581 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$58,899,000— Margins · derivedOperating margin65.6%
Net margin69.3%
ended Jun 30, 2024 · filed Jul 31, 2024 · 31 d after period end